NSE Nifty 50: Top 5 stock losers of April 29, 2025

In this article, we will explore the technical indicators of some of the low-performing stocks on the Indian stock market, including COALINDIA, DRREDDY, ONGC, SUNPHARMA, and ULTRACEMCO.

By looking at these stocks through the lens of key technical factors, we aim to better understand their price movements, trends, and potential future performance.

Analysis for Coal India - April 29, 2025

Coal India Performance: Coal India's stock opened at 397.15 and closed at 389.10, marking a decline of 2.03% with a points change of -8.05. The trading volume for the day was approximately 6.26 million shares. Coal India's RSI stands at 47.85, suggesting a neutral momentum, while the MACD indicates a downward trend compared to its signal line. Positioned within the 'Energy' sector in the 'Thermal Coal' industry, the company has a market cap of approximately ₹2,397,918 million and a PE Ratio of 6.988.

Relationship with Key Moving Averages

Coal India is trading close to its 50 EMA of 388.49, slightly below its current closing price of 389.10, suggesting near-term consolidation. It is trading below the 200 EMA of 399.88, which indicates potential resistance to longer-term upward momentum. The 10 EMA and 20 EMA values are higher than the closing price, suggesting recent downward pressure.

Moving Averages Trend (MACD)

Coal India's MACD is currently at 2.71, which is below its MACD Signal of 3.48. This indicates a bearish trend momentum in the short term. Investors might consider caution as the stock shows potential for further downside movement unless there is a reversal in the trend.

RSI Analysis

The Relative Strength Index (RSI) for Coal India is 47.85, indicating that the stock is neither overbought nor oversold, as it is close to the middle of the standard RSI range (30 to 70). This suggests a neutral market sentiment towards the stock at the moment.

Analysis for Dr Reddys Labs - April 29, 2025

Dr Reddy's Laboratories showed a decrease in its stock price with a close at 1176.0, down by approximately 1.89% from the previous close of 1198.7. It remains traded under high volume with 1,662,833 shares and maintains a market cap of 979.25 billion INR. The stock's RSI indicates moderate momentum at 53.31, amidst its sector of Healthcare, specifically in Drug Manufacturers - Specialty & Generic, in India.

Relationship with Key Moving Averages

Dr Reddys Labs closed at 1176.0, slightly above its 50-day EMA of 1172.05 and its 10-day EMA of 1173.49, indicating a potential short-term bullish sentiment. However, it remains below the 200-day EMA of 1225.44, suggesting a longer-term bearish trend.

Moving Averages Trend (MACD)

Dr. Reddy's Laboratories is experiencing a positive MACD divergence, as the MACD line (8.27) is above the Signal line (1.97), indicating a potential bullish momentum. This suggests that the stock may have an upward price movement, although other indicators, such as the RSI and moving averages, should also be considered for a comprehensive analysis.

RSI Analysis

Dr Reddys Labs has an RSI of 53.31, indicating a neutral momentum where the stock is neither overbought nor oversold. This level suggests a balanced sentiment among traders, with no significant bullish or bearish trend currently dominating.

Analysis for ONGC - April 29, 2025

### ONGC Performance On 13 January 2022, ONGC opened at 251.24 and closed at 245.68, showing a negative movement with a -1.96% change from the previous close of 250.60. The trading volume was at 8,028,091 shares. ONGC operates in the Energy sector, specifically in the Oil & Gas Integrated industry in India. With a P/E ratio of 7.93 and an EPS of 31.0, the company's market cap stands at ₹3,090,727,829,504. Key technical indicators include a 50 EMA of 240.38, a 200 EMA of 248.11, and an RSI of 54.13, indicating a relatively neutral momentum.

Relationship with Key Moving Averages

The stock price of ONGC closed at 245.68, which is below the 50-day EMA of 240.38 but above the 10-day EMA of 245.24 and above the 20-day EMA of 242.04. This suggests a short-term bullish momentum, as the closing price is closer to its shorter-term moving averages. The 200-day EMA is at 248.11, which the closing price is slightly below, indicating a struggle to maintain a long-term upward trend.

Moving Averages Trend (MACD)

ONGC shows a positive MACD, indicating a potential bullish trend, as the MACD line (3.39) is above the Signal line (2.19). This suggests there might be upward momentum in the stock price.

RSI Analysis

The Relative Strength Index (RSI) for ONGC is 54.13, which indicates the stock is in neutral territory. It lies between the commonly watched range of 30 (oversold) and 70 (overbought), suggesting that ONGC does not exhibit strong bullish or bearish momentum at this time.

Analysis for SUN Pharma - April 29, 2025

SUN Pharma Performance: SUN Pharma's stock opened at 1845 and closed at 1805.5, reflecting a decrease of approximately 1.96% from its previous close of 1841.6. The stock experienced a high of 1846 and a low of 1797, with a trading volume of 2,886,127. Currently, the stock trades above its 50-EMA (1730.24) and 200-EMA (1703.41) but below its 10-EMA (1776.10) and 20-EMA (1750.32). The RSI stands at 59.26, suggesting a neutral momentum, while the MACD indicates a bullish signal. SUN Pharma, part of the Healthcare sector and operating in the Drug Manufacturers - Specialty & Generic industry in India, holds a market cap of approximately 4,331,990,417,408, with a PE ratio of 37.85 and an EPS of 47.7.

Relationship with Key Moving Averages

The closing price of SUN Pharma at 1805.5 lies above its 50-day and 200-day EMAs, which are 1730.24 and 1703.41, respectively. However, it is above the 10-day EMA of 1776.10 and the 20-day EMA of 1750.32, indicating a bullish momentum in the short to medium term.

Moving Averages Trend (MACD)

MACD Analysis for SUN Pharma: The MACD for SUN Pharma is 27.59, which is above the MACD Signal of 16.71. This typically indicates a bullish trend as the MACD line is trending above the signal line, suggesting potential upward momentum in the stock price.

RSI Analysis

The RSI for SUN Pharma is 59.26, which indicates a neutral zone, suggesting neither overbought nor oversold conditions. This implies that the stock is currently experiencing balanced buying and selling pressure.

Analysis for UltraTech Cement - April 29, 2025

UltraTech Cement has experienced a decrease in its stock performance, closing at 11,869, down by 245 points from the previous close with a percentage change of -2.02%. Despite this decline, the company maintains a relatively strong RSI of 58.1, indicating some level of investor interest, and the stock remains above its 50 and 200-day EMA, highlighting long-term strength. UltraTech Cement operates within the Basic Materials sector and specializes in building materials in India.

Relationship with Key Moving Averages

UltraTech Cement's closing price of 11,869 is below its 10-day EMA of 11,917.21, indicating short-term bearish momentum. However, it remains above both its 50-day EMA of 11,408.88 and 200-day EMA of 11,092.28, suggesting a longer-term bullish trend.

Moving Averages Trend (MACD)

Based on the given data for UltraTech Cement, the MACD value is 263.49, which is above the Signal Line of 240.26. This indicates a potential bullish trend or buying signal as the MACD line is crossing above the signal line, suggesting that the momentum may be in favor of the buyers.

RSI Analysis

RSI Analysis for UltraTech Cement: The RSI (Relative Strength Index) of UltraTech Cement is 58.10, indicating that the stock is in a neutral zone. This suggests that the stock is neither overbought nor oversold at this point, reflecting moderate momentum.